China Clarifies Position on Forged Trial Data As 30 Applications Are Rejected
Executive Summary
As more new drug applications get rejected under the China Food and Drug Administration’s drive to stamp out trial data forgery, the regulator has issued draft guidance to clarify its position on data integrity breaches.